Tuesday, 20 October 2026
Nirsevimab backed for national program, Antidepressant PBS restrictions rethink, NSW bat exposures surge
- 01
PBAC recommends nirsevimab for infant RSV prevention through NIP
The PBAC has recommended adding nirsevimab to the National Immunisation Program for babies and children up to two years of age to protect against respiratory syncytial virus. It said the monoclonal antibody would provide extra protection for infants missed by the maternal RSV vaccination program, including those born within two weeks of maternal RSVpreF vaccination, and children at risk of severe disease through their first or second RSV season. Nirsevimab is currently available through separate state and territory-funded programs with differing eligibility criteria, and child health experts welcomed the prospect of a consistent national approach. An April legislative amendment enabled the recommendation by broadening the NIP’s definition of a vaccine to include passive immunisation strategies. The Federal Government will decide whether to add nirsevimab to the NIP, with Immunisation Coalition Chair Dr Rod Pearce calling for inclusion by February 2027.
via RACGP newsGP
- 02
PBAC backs removal of antidepressant indication restrictions
PBAC has backed proposed changes to PBS restrictions for commonly prescribed antidepressants. The changes would remove indication-specific restrictions and could reduce patients’ out-of-pocket costs. The source provides limited detail about the proposal or its implementation.
- 03
NSW bat bites and scratches rise fourfold
NSW recorded 43 bat bite or scratch assessments from 28 September to 10 October, up from 10 in the corresponding fortnight last year. Exposures occurred across several coastal regions, while food shortages were driving unusual flying-fox behaviour along the state’s eastern coastline. NSW Health instructed clinicians to immediately clean wounds for at least 15 minutes and notify their local public health unit, which determines whether rabies vaccine and human rabies immunoglobulin are required. Australian bat lyssavirus is almost always fatal after symptoms develop, and all four human cases recorded in Australia since the virus was identified in 1996 were fatal. Although the warning centred on NSW, the virus is present in bats across Australia.
- 04
Unapproved peptide use linked to wave of NSW ED presentations
A wave of emergency department presentations in NSW has been linked to unapproved peptide use. The state’s chief health officer warned that professional-looking websites and labels do not guarantee a product is reliable or safe to use. The source gives limited detail and does not specify presentation numbers, products or patient outcomes.
- 05
Retatrutide cut pain and weight in obesity-related knee osteoarthritis
Once-weekly retatrutide significantly reduced knee pain and body weight over 80 weeks in an Eli Lilly-funded phase 3 trial of 2339 adults with obesity but without diabetes. Among 574 participants with moderate to severe knee osteoarthritis, mean WOMAC pain scores fell by 3.5 and 3.6 points with the 9 mg and 12 mg doses, respectively, compared with 1.9 points with placebo. Mean body weight fell by 17.6% with 4 mg, 23.7% with 9 mg and 25.0% with 12 mg, versus 3.9% with placebo, alongside improvements in physical function and cardiometabolic measures. Gastrointestinal symptoms predominated, while adverse event-related discontinuation ranged from 4.1% to 11.1% across retatrutide doses, compared with 4.6% for placebo. The triple GIP, GLP-1 and glucagon receptor agonist is not approved anywhere, and the trial did not establish long-term safety, durability, effects on structural disease progression or whether pain improvement resulted entirely from weight loss.
- 06
Utah authorises AI acne prescribing trial with initial doctor review
Utah has become the first US state to allow artificial intelligence to issue new prescriptions, authorising Nolla Health to prescribe acne medicines. The system can prescribe to adults in Utah with mild to moderate acne after reviewing facial scans and medical information submitted through the Nolla Derm app. During the trial’s initial phase, two Utah-licensed doctors must review every prescription before it is issued. The agreement allows independent AI prescribing in later phases, provided specified performance requirements and safeguards are met.
via BMJ
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.